Is intermittent androgen-deprivation therapy beneficial for patients with advanced prostate cancer?

Androgen-deprivation therapy in men with metastatic prostate cancer: less may not necessarily be more

(2013) Mark Ng Tang Fui et al.   ASIAN JOURNAL OF ANDROLOGY

Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer

(2013) Tanya B. Dorff et al.   CURRENT OPINION IN UROLOGY

Intermittent Androgen-deprivation Therapy in Prostate Cancer: A Critical Review Focused on Phase 3 Trials

(2013) Alessandro Sciarra et al.   EUROPEAN UROLOGY

Treatment of Prostate Cancer With Intermittent Versus Continuous Androgen Deprivation: A Systematic Review of Randomized Trials

(2013) Saroj Niraula et al.   JOURNAL OF CLINICAL ONCOLOGY

Intermittent versus Continuous Androgen Deprivation in Prostate Cancer

(2013) Maha Hussain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial

(2012) Nicolas Mottet et al.   BJU INTERNATIONAL

Androgen deprivation therapy: past, present and future

(2012) F. Schröder et al.   BJU INTERNATIONAL

Advanced Prostate Cancer Treated with Intermittent or Continuous Androgen Deprivation in the Randomised FinnProstate Study VII: Quality of Life and Adverse Effects

(2012) Arto J. Salonen et al.   EUROPEAN UROLOGY

132 Pooled analysis of two protocols of intermittent hormonal therapy, in advance prostatic cancer

(2012) F.M.V. Calais Da Silva Junior et al.   EUROPEAN UROLOGY SUPPLEMENTS

The FinnProstate Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer

(2012) Arto J. Salonen et al.   JOURNAL OF UROLOGY

The benefits of intermittent androgen-deprivation therapy

(2012) Timur Mitin et al.   Nature Reviews Clinical Oncology

Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy

(2012) Juanita M. Crook et al.   NEW ENGLAND JOURNAL OF MEDICINE

Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy

(2012) U W Tunn et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Identifying the Best Candidate for Radical Prostatectomy Among Patients with High-Risk Prostate Cancer

(2011) Alberto Briganti et al.   EUROPEAN UROLOGY

Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study

(2011) Tanya B. Dorff et al.   JOURNAL OF CLINICAL ONCOLOGY

Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials

(2011) Anthony V D'Amico et al.   LANCET ONCOLOGY

The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen Deprivation

(2011) Daniel Keizman et al.   PROSTATE

Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer

(2011) Johan F. Langenhuijsen et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?

(2010) Mathis Grossmann et al.   CLINICAL ENDOCRINOLOGY

An update on androgen deprivation therapy for prostate cancer

(2010) Nima Sharifi et al.   ENDOCRINE-RELATED CANCER

Does Local Treatment of the Prostate in Advanced and/or Lymph Node Metastatic Disease Improve Efficacy of Androgen-Deprivation Therapy? A Systematic Review

(2010) Paul C.M.S. Verhagen et al.   EUROPEAN UROLOGY

Androgen Deprivation Therapy for Prostate Cancer: Recommendations to Improve Patient and Partner Quality of Life

(2010) Stacy Elliott et al.   Journal of Sexual Medicine

Prostate-specific antigen kinetics in localized and advanced prostate cancer

(2009) John M. Fitzpatrick et al.   BJU INTERNATIONAL

Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?

(2009) Massimo Perachino et al.   BJU INTERNATIONAL

Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group

(2009) Fernando E.C. Calais da Silva et al.   EUROPEAN UROLOGY

Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature

(2009) Per-Anders Abrahamsson   EUROPEAN UROLOGY

A Holistic Approach to Androgen Deprivation Therapy: Treating the Cancer without Hurting the Patient

(2009) Bertrand Tombal   UROLOGIA INTERNATIONALIS

Continuous versus Six Months a Year Maximal Androgen Blockade in the Management of Prostate Cancer: A Randomised Study

(2008) Jacques Irani et al.   EUROPEAN UROLOGY

Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610

(2008) Mack Roach et al.   JOURNAL OF CLINICAL ONCOLOGY

The continued debate: Intermittent vs. continuous hormonal ablation for metastatic prostate cancer

(2008) Martin Gleave et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS